Overview
I am the Clinical Director of the H&N Medical Oncology Program and the Director of the H&N Clinical Research Unit (CRU). I am a clinical and translational investigator with a focus on the development of new therapies for head and neck, thyroid, and salivary gland cancers. My primary focus involves bringing innovative clinical trials for these patients at Duke. Delivering excellent cancer care through a multidisciplinary clinic setup is the cornerstone of my philosophy.
Current Appointments & Affiliations
Associate Professor of Medicine
·
2024 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2024 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Abstract PO1-03-10: Differential microbial metabolic pathways associated with resistance to neoadjuvant immunotherapy in locally advanced triple negative breast cancer
Conference Cancer Research · May 2, 2024 AbstractDifferential microbial metabolic pathways associated with resistance to neoadjuvant immunotherapy in locally advanced triple negative breast cancer Background: It has previously been shown that micro ... Full text CiteAbstract CT226: Phase 2 study of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with head and neck squamous cell carcinoma (HNSCC) previously treated with checkpoint inhibitor
Conference Cancer Research · April 5, 2024 AbstractBACKGROUND: FLX475 (tivumecirnon) is a selective CCR4 antagonist designed to block the recruitment of immunosuppressive regulatory T cells (Treg) into the tumor microenvironment. The FLX475-02 trial ... Full text CiteA Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Journal Article Clin Cancer Res · November 14, 2023 PURPOSE: This open-label, single-arm, phase II study evaluated the vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) rivoceranib in patients with recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC). PATIENTS AN ... Full text Link to item CiteRecent Grants
A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Clinical TrialPrincipal Investigator · Awarded by Bicara Therapeutics Inc. · 2025 - 2030A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF ZANZALINTINIB (XL092) IN COMBINATION WITH PEMBROLIZUMAB VS PEMBROLIZUMAB IN THE FIRST-LINE TREATMENT OF SUBJECTS WITH PD-L1 POSITIVE RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCIN
Clinical TrialPrincipal Investigator · Awarded by Exelixis, Inc · 2024 - 2029InnovaTV207 SGNTV 001 Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors. SGNTV001
Clinical TrialPrincipal Investigator · Awarded by Seagen, Inc · 2024 - 2029View All Grants
Education, Training & Certifications
Maulana Azad Medical College (India) ·
2001
M.D.